Neurological Aspects of the COVID-19 Pandemic

Abstract

The recent outbreak of the novel coronavirus, SARS-CoV-2 – which causes COVID-19 – has rapidly reached pandemic proportions, causing widespread morbidity and mortality It has had a major impact on society in general, and in medicine and health in particular Although primarily a potentially fatal respiratory pathogen, SARS-CoV-2, like other coronaviruses, can be neurotropic Its receptor, angiotensin-converting enzyme 2 (ACE2), is expressed in endothelial cells in the brain and can be induced in neural cells COVID-19 is therefore of high relevance to neurological disease Indeed, various neurological manifestations are increasingly being reported On the other hand, COVID-19 has a major impact on people with certain neurological diseases Patients with neuroimmune disorders such as multiple sclerosis or myasthenia gravis who are on immunomodulatory or immunosuppressive treatments may be more susceptible to infection or have a more severe disease due to a blunted immune response Patients with many neurological disorders may be at risk of severe COVID-19 infection, due to immobility, frailty, disability, diminished respiratory capacity or cognitive dysfunction Disease-specific patient organisations and neurological societies have been prompt in providing advice and generating guidelines for various neurological conditions Local, national and international registers are being created and will be essential in monitoring the disease and its outcomes New knowledge about COVID-19, including issues of relevance to neurology, is generated daily This review presents some succinct background information on coronaviruses and its neuro-invasive potential, the current knowledge of neurological manifestations, and the impact of COVID-19 on individuals with neurological disease Some disease-specific recommendations are briefly listed or referenced